Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jonathan Demchick has maintained an Equal-Weight rating on NuVasive (NASDAQ:NUVA) and raised the price target from $40 to $45.
August 04, 2023 | 6:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on NuVasive and raised the price target from $40 to $45, which could potentially lead to a positive market reaction.
The raised price target by Morgan Stanley indicates a positive outlook for NuVasive. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100